Literature DB >> 19289741

Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes.

Heinz Wiendl1, Reinhard Hohlfeld.   

Abstract

In this essay, we draw attention to some recent downsides and surprises of multiple sclerosis (MS) therapeutics. These include experiences with recent head-to-head trials of interferon-beta and glatiramer acetate, dose escalation trials, frustrating efforts with progressive MS trials, failures of smart concepts and designer therapies, and harsh lessons from newly observed adverse reactions.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19289741     DOI： 10.1212/01.wnl.0000344417.42972.54

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  20 in total

1.  Autoimmunity's next top models.

Authors:  Hartmut Wekerle; Alexander Flügel; Lars Fugger; Georg Schett; David Serreze
Journal:  Nat Med       Date:  2012-01-06       Impact factor: 53.440

Review 2.  Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease.

Authors:  Hans Lassmann
Journal:  J Neural Transm (Vienna)       Date:  2011-03-05       Impact factor: 3.575

3.  Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier.

Authors:  Andreas Schulte-Mecklenbeck; Urvashi Bhatia; Tilman Schneider-Hohendorf; Nicholas Schwab; Heinz Wiendl; Catharina C Gross
Journal:  J Vis Exp       Date:  2017-04-05       Impact factor: 1.355

Review 4.  Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges.

Authors:  Paulo Fontoura
Journal:  MAbs       Date:  2010 Nov-Dec       Impact factor: 5.857

5.  Progressive multiple sclerosis and mood disorders.

Authors:  Lorena Lorefice; G Fenu; G Trincas; M F Moro; J Frau; G C Coghe; E Cocco; M G Marrosu; M G Carta
Journal:  Neurol Sci       Date:  2015-04-22       Impact factor: 3.307

6.  Targeted metabolomics approach for identification of relapsing-remitting multiple sclerosis markers and evaluation of diagnostic models.

Authors:  Marat F Kasakin; Artem D Rogachev; Elena V Predtechenskaya; Vladimir J Zaigraev; Vladimir V Koval; Andrey G Pokrovsky
Journal:  Medchemcomm       Date:  2019-08-12       Impact factor: 3.597

7.  Demyelination patterns in a mathematical model of multiple sclerosis.

Authors:  M C Lombardo; R Barresi; E Bilotta; F Gargano; P Pantano; M Sammartino
Journal:  J Math Biol       Date:  2016-12-30       Impact factor: 2.259

Review 8.  Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.

Authors:  Daniel Ontaneda; Robert J Fox; Jeremy Chataway
Journal:  Lancet Neurol       Date:  2015-02       Impact factor: 44.182

Review 9.  Myelin Basic Protein Citrullination in Multiple Sclerosis: A Potential Therapeutic Target for the Pathology.

Authors:  Lei Yang; Dewei Tan; Hua Piao
Journal:  Neurochem Res       Date:  2016-04-21       Impact factor: 3.996

10.  Subclinical CNS inflammation as response to a myelin antigen in humanized mice.

Authors:  Morad Zayoud; Khalifa El Malki; Katrin Frauenknecht; Bettina Trinschek; Luise Kloos; Khalad Karram; Florian Wanke; Julia Georgescu; Udo F Hartwig; Clemens Sommer; Helmut Jonuleit; Ari Waisman; Florian C Kurschus
Journal:  J Neuroimmune Pharmacol       Date:  2013-05-03       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.